CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Raja Ramachandran, Ashok K. Yadav, Vinod Kumar and 2 more
Kidney International Reports · 2017
doi:10.1016/j.ekir.2016.08.019 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Varied dosing regimens of rituximab (RTX) have been successfully used in the management of primary membranous nephropathy (PMN).1,2 An ideal RTX dose and the long-term adverse effect of a larger cumulative dose are not clear. CD19 levels are used to gauge the drug effect.1 Economic viability is a major part of any new therapeutic regimen. Low-dose RTX (100 mg) has been successfully used in ABO incompatible renal transplant.3 In the present study, we report a similar approach of CD19 depletion using 100 mg of RTX in the management of M-type phospholipase A2 receptor antibody (aPLA2R)-associated PMN refractory, dependent on or intolerant to conventional immunosuppressive regimens recommended by Kidney Disease: Improving Global Outcomes.
Abstract licence: CC BY-NC-ND
References6
6 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.